Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner in Hematology/Oncology, University of California San Francisco

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner in Hematology/Oncology, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago. Ms. Zitella holds certifications as an Acute Care Nurse Practitioner and an Advanced Oncology Certified Nurse.

Her clinical expertise includes patients with hematologic malignancies receiving chemotherapy, immunotherapy, targeted therapy, investigational agents, hematopoietic cell transplantation, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, videos, and book chapters. Ms. Zitella co-edited the Hematologic Malignancies in Adults textbook, which was awarded an American Medical Writers Association Medical Book Award Honorable Mention.

Ms. Zitella is actively involved with the Advance Practice Provider Oncology Summit (APPOS), Advanced Practitioner Society for Hematology and Oncology (APSHO), the Oncology Nursing Society (ONS), and the CLL Society. She serves on Medical Advisory Board of the CLL Society, the Journal of Advanced Practitioner in Oncology editorial board, and several oncology conference planning committees. Ms. Zitella is the proud recipient of the ONS Excellence in Medical Oncology award, the DAISY award, and the inaugural Stanford Health Care Advanced Practice Provider of the Year award.

Laura J. Zitella

Laura's Shared Resources

Global Experts Tackle Infection Risks in Multiple Myeloma, Call for Unified Prevention Guidelines

In patients with multiple myeloma, infection is the primary cause of morbidity and mortality, influenced by a combination of the disease itself, treatments, and individual patient factors. The risk of...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

FDA ODAC Backs Ide-Cel in Multiple Myeloma, Highlighting KarMMa-3 Trial Results

The FDA Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 in favor of using intravenous infusion of idecabtagene vicleucel (ide-cel; Abecma) for patients with pretreated relapsed/refractory multiple myeloma. This...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

DREAMM-8 Trial: Belantamab Mafodotin Shows Promise in Treating Multiple Myeloma

GSK, the manufacturer of the antibody-drug conjugate belantamab mafodotin-blmf (Blenrep), has announced positive top-line findings from the phase 3 DREAMM-8 trial for belantamab mafodotin combined with pomalidomide and dexamethasone in...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share